Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

40P - Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer

Date

09 Dec 2020

Session

e-Poster Display Session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Renato Cunha

Citation

Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391

Authors

R. Cunha1, M. Fernandes2, S. Abreu2, C. Oliveira2, J. Dias2

Author affiliations

  • 1 Hospital Espírito Santo, EPE – Évora, Évora/PT
  • 2 Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E, Porto/PT
More

Abstract 40P

Background

Immune checkpoint inhibitors (ICI) changed the paradigm of cancer treatment. Atezolizumab (anti-PD-L1), nivolumab and pembrolizumab (anti-PD-1) are standard of care in patients with previously treated advanced non-small cell lung cancer (NSCLC). Our aim is to assess efficacy and safety of ICIs in this setting, in a cancer institute, and factors related with survival.

Methods

Retrospective observational study of patients with metastatic NSCLC treated in second or further line with ICIs, from 2015 to 2019. Statistical analysis with IBM SPSS software v.25. Overall survival (OS) and progression-free survival (PFS) calculated using Kaplan-Meier curves and factors associated with survival using univariate and multivariate Cox regression analysis. Patient stratification according to age, smoking status, comorbidities, driver mutations, ECOG PS and PD-L1 expression.

Results

96 patients were analyzed, with median follow-up 18 months. Mean age ate the start of ICIs 65 years, 80% male, 79% ECOG 1; PD-L1 was negative in 33% and ≥50% in 23%; 43% treated with nivolumab, 39% pembrolizumab, 18% atezolizumab. 7% presented grade 3-4 adverse events (AEs). Overall response rate (ORR) was 20%, median PFS was 4.5 months and median OS was 12.9 months. PFS was significantly longer in patients without comorbidities (HR 0.56, IC 0.32-0.98; p=0.044) and ECOG 0-1 (HR 0.25, 0.10-0.62; p=0.003). OS was longer in patients with ECOG PS 0-1 (HR 0.20, 0.08-0.53; 0.001). Anti-PD-1 had superior disease control rate (DCR) than anti-PD-L1 (OR 9.93; p=0.001) and PFS was longer with anti-PD-1 (6.4 months) versus anti-PD-L1 (2.3 months; HR 0.27, 0.14-0.53; p<0.001). All subgroups showed benefit from anti-PD-1, except patients under 65 years, with driver mutations and ECOG PS 2. No significant differences were observed in OS or AEs. PD-L1 status did not impact PFS or OS in any of the performed analysis.

Conclusions

This study confirms benefit of ICI in the treatment of NSCLC after first line in our population, with similar results to the literature. We also report a significant relation between absence of comorbidities and ECOG PS with survival. Treatment with anti-PD-1 showed superior DCR and PFS versus anti-PD-L1, but longer follow-up is needed to clarify OS differences.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.